The dabrafenib–trametinib combination administered in two patients with BRAF p.V600E tumors entailed adverse events of grade 3–4, including skin rashes, pyrexia and a hydrothorax episode (in a patient with pelvic spindle-cell STS), necessitating dose reduction and therapy breaks in both cases. This evidence concerns the gene BRAF and Fever.